Off-the-shelf T-cell therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.Blood advances · 2024
   Trial
2. Clinical development of allogeneic chimeric antigen receptor αβ-T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
   Review
3. Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells.Blood · 2023
   Article
4. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.Journal for immunotherapy of cancer · 2021
   Article
5. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.Seminars in immunopathology · 2019
   Review
6. How an alloreactive T-cell receptor achieves peptide and MHC specificity.Proceedings of the National Academy of Sciences of the United States of America · 2017
   Article
7. Challenges and opportunities of allogeneic donor-derived CAR T cells.Current opinion in hematology · 2015
   Review
8. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2014
   Article
9. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.Blood · 2012
   Article
10. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry.Journal of translational medicine · 2012
    Article

Corrections and comments

• Comment on
  Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.2010

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.